---
title: EpiPen Maker Mylan Has New Reasons to Worry About Its Cash Cow
description: In a blog post, the FDA addressed concerns about the price of the EpiPen and its efforts to bring competing products to patients.
authors:
  - name: Martha C. White
    role: Reporter
    url: https://money.com/author/martha-c-white/
    education: BA, English, Princeton University
    at_money_since: 2015
    articles: 358
    covers:
      - Business
      - Banking
      - Career Advice
      - Credit
      - Credit Cards
      - Debt
      - Economy and Politics
      - Education
      - Federal Reserve Rate Cuts
      - Health and Wellness
      - Housing
      - Identity Theft
      - Insurance
      - Investing
      - Lifestyle
      - Loans
      - Mortgages
      - Personal Finance
      - Professional Services
      - Retirement
      - Shopping
      - Taxes
      - Technology
    also_seen_in:
      - The New York Times
      - The Wall Street Journal
      - CNN
      - Kiplinger Personal Finance
      - Time
    social:
      - https://www.linkedin.com/in/martha-c-white/
published: '2016-09-14T21:34:38.000Z'
modified: '2024-05-16T11:40:43.000Z'
section: Business
tags:
  - EpiPen
  - FDA
  - Heather Bresch
  - Mylan
  - prescription drug prices
  - pubdesk
word_count: 222
canonical: https://money.com/epipen-mylan-price-competition/
type: Article
source: structured-blocks
---

> **Disclosure:** We research all brands listed and may earn a fee from our partners. Research and financial considerations may influence how brands are displayed. Not all brands are included. [Learn more](https://money.com/page/disclaimer/).

![mylan-fda](https://img.money.com/2016/09/mylan-fda.jpeg)

Even as drug company Mylan continues to be under scrutiny for its attempts to justify a 500% price hike for the EpiPen and its executives' outsized pay packages, there are indications that something both more prosaic and more threatening to its bottom line might be coming: competition.

"Recent news about the price spike of EpiPen has caused concern," the Food & Drug Administration said in a [blog post](http://blogs.fda.gov/fdavoice/index.php/2016/09/fda-and-access-to-medications/) on Wednesday. "We stand ready to quickly review additional applications that come to us from manufacturers, especially applications for generic versions." Mylan has said it will make its own generic EpiPen, although critics have pointed out that could earn the company even more money than its $608 name-brand EpiPen.

Fortunately, Mylan might have more company soon. "The good news is that the FDA has already approved four epinephrine auto-injectors to treat anaphylaxis in an emergency, and two are currently marketed," the agency said in its blog post. "We at the FDA are also doing all we can to encourage manufacturers to develop innovative new auto-injectors... To help development, we built a roadmap that will get these products on the market faster," it said.

That means [more](https://money.com/cheaper-epipen-alternatives-price/) alternatives could be on the way, which is likely to be a relief for the families and policymakers who have complained about the [slow pace](http://www.npr.org/sections/health-shots/2016/09/01/492235796/fda-fees-on-industry-havent-fixed-delays-in-generic-drug-approvals) of drug approvals.

```json
{
  "@context": "https://schema.org",
  "@graph": [
    {
      "@type": "BreadcrumbList",
      "@id": "https://money.com/epipen-mylan-price-competition/#breadcrumb",
      "itemListElement": [
        {
          "@type": "ListItem",
          "position": 1,
          "name": "Home",
          "item": "https://money.com"
        },
        {
          "@type": "ListItem",
          "position": 2,
          "name": "Business",
          "item": "https://money.com/business/"
        },
        {
          "@type": "ListItem",
          "position": 3,
          "name": "Small Business",
          "item": "https://money.com/small-business/"
        },
        {
          "@type": "ListItem",
          "position": 4,
          "name": "EpiPen Maker Mylan Has New Reasons to Worry About Its Cash Cow"
        }
      ]
    },
    {
      "@type": "WebSite",
      "@id": "https://money.com/#website",
      "url": "https://money.com",
      "name": "Money",
      "publisher": {
        "@id": "https://money.com/#organization"
      }
    },
    {
      "@type": "WebPage",
      "@id": "https://money.com/epipen-mylan-price-competition/#webpage",
      "url": "https://money.com/epipen-mylan-price-competition/",
      "name": "EpiPen Maker Mylan Has New Reasons to Worry About Its Cash Cow",
      "isPartOf": {
        "@id": "https://money.com/#website"
      },
      "datePublished": "2016-09-14T21:34:38.000Z",
      "mainEntity": {
        "@id": "https://money.com/epipen-mylan-price-competition/"
      },
      "inLanguage": "en-US",
      "breadcrumb": {
        "@id": "https://money.com/epipen-mylan-price-competition/#breadcrumb"
      },
      "dateModified": "2024-05-16T11:40:43.000Z"
    },
    {
      "@type": "Article",
      "headline": "EpiPen Maker Mylan Has New Reasons to Worry About Its Cash Cow",
      "articleSection": "Business",
      "image": [
        {
          "@type": "ImageObject",
          "url": "https://img.money.com/2016/09/mylan-fda.jpeg",
          "width": 5760,
          "height": 3687,
          "caption": "mylan-fda"
        }
      ],
      "author": [
        {
          "@type": "Person",
          "name": "Martha C. White",
          "url": "https://money.com/author/martha-c-white/",
          "@id": "https://money.com/author/martha-c-white/#author",
          "image": "https://img.money.com/2014/01/martha.png?w=350&h=430&crop=1",
          "email": "martha@money.com",
          "jobTitle": "Reporter",
          "alumniOf": "BA, English, Princeton University",
          "subjectOf": [
            {
              "@type": "WebPage",
              "url": "https://www.nytimes.com",
              "name": "The New York Times"
            },
            {
              "@type": "WebPage",
              "url": "https://www.wsj.com",
              "name": "The Wall Street Journal"
            },
            {
              "@type": "WebPage",
              "url": "https://www.cnn.com",
              "name": "CNN"
            },
            {
              "@type": "WebPage",
              "url": "https://www.kiplinger.com/",
              "name": "Kiplinger Personal Finance"
            },
            {
              "@type": "WebPage",
              "url": "https://www.time.com",
              "name": "Time"
            }
          ],
          "sameAs": [
            "https://www.linkedin.com/in/martha-c-white/"
          ],
          "worksFor": {
            "@id": "https://money.com/#organization"
          }
        }
      ],
      "publisher": "https://money.com/#organization",
      "datePublished": "2016-09-14T21:34:38.000Z",
      "description": "In a blog post, the FDA addressed concerns about the price of the EpiPen and its efforts to bring competing products to patients.",
      "abstract": "In a blog post, the FDA addressed concerns about the price of the EpiPen and its efforts to bring competing products to patients.",
      "@id": "https://money.com/epipen-mylan-price-competition/",
      "inLanguage": "en-US",
      "dateModified": "2024-05-16T11:40:43.000Z",
      "wordCount": 222,
      "keywords": [
        "EpiPen",
        "FDA",
        "Heather Bresch",
        "Mylan",
        "prescription drug prices",
        "pubdesk"
      ],
      "about": [
        {
          "@type": "Thing",
          "name": "Business",
          "sameAs": [
            "https://en.wikipedia.org/wiki/Business"
          ]
        },
        {
          "@type": "Thing",
          "name": "Small business",
          "sameAs": [
            "https://en.wikipedia.org/wiki/Small_business"
          ]
        }
      ]
    }
  ]
}
```
